How Fast Do You Lose Weight on Zepbound: Week-by-Week Timeline and What Actually Predicts Your Results

Reviewed by FormBlends Medical Team · Corrected and updated September 5, 2026 · sources listed below

Key Takeaways

• In SURMOUNT-1, mean weight change at week 72 was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, versus 3.1% on placebo, after a dose-escalation period of up to 20 weeks (Zepbound label, revised 08/2026; Jastreboff et al., NEJM 2022).
• Neither the label nor the NEJM paper publishes pounds-per-week values. The time course appears only as a graph, so any week-by-week table you see online, including one that used to appear on this page, is an estimate rather than a published result.
• On 15 mg, 90.9% of participants lost at least 5% of body weight, 83.5% at least 10%, 70.6% at least 15% and 56.7% at least 20% (label Table 2). Individual results spread widely around the mean.
• Steady-state drug levels are reached after about 4 weeks of once-weekly dosing and the half-life is about 5 days (label section 12.3), which is why each new dose takes roughly a month to show its full effect.

The short answer

As of September 5, 2026, there is no published week-by-week weight loss figure for Zepbound (tirzepatide). What is published is the endpoint: in the 72-week SURMOUNT-1 trial, adults with obesity lost a mean 15.0% (5 mg), 19.5% (10 mg) or 20.9% (15 mg) of body weight, versus 3.1% on placebo, with doses escalated over up to 20 weeks (Zepbound label, revised 08/2026). Loss is slower during escalation and flattens toward the end of the trial, but the exact pace at each week is shown only as a graph in the label.

Table of contents

1. The week-by-week weight loss curve from the SURMOUNT trials
2. What most articles get wrong about "average" weight loss
3. The four-phase tirzepatide weight loss model
4. Fast responders vs slow responders
5. The dose-response relationship: does higher dose mean faster loss?
6. Factors that predict whether you'll lose weight quickly
7. When weight loss stalls and what it means
8. Comparing Zepbound speed to semaglutide (Wegovy, Ozempic)
9. The decision tree: when to escalate dose vs stay patient
10. What to do if you're losing weight too slowly
11. Correction, September 2026: what the label reports
12. What the lost weight is made of (SURMOUNT-1 DXA substudy, 2025)
13. What happens if you stop (SURMOUNT-4, JAMA 2024)
14. FAQ
15. Sources

The week-by-week weight loss curve from the SURMOUNT trials

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked 2,539 adults with obesity over 72 weeks, including a dose-escalation period of up to 20 weeks. The published results are the week-72 endpoints below; the trial did not publish weekly pounds-per-week values.

Correction, September 2026: an earlier version of this section presented a table of weekly loss (0.8 to 2.4 pounds per week) and cumulative percentages at weeks 4, 8, 12, 20, 32 and 52 as published SURMOUNT-1 data. Those interim numbers could not be traced to the NEJM paper, its abstract, or the Zepbound label, and have been removed. The label shows the time course only as a graph (Figure 3).

SURMOUNT-1 arm	Mean weight change at week 72	Lost at least 5%	Lost at least 10%	Lost at least 15%	Lost at least 20%
Placebo	-3.1%	34.5%	18.8%	8.8%	3.1%
Tirzepatide 5 mg	-15.0%	Responder rates by dose are in label Table 2
Tirzepatide 10 mg	-19.5%	Responder rates by dose are in label Table 2
Tirzepatide 15 mg	-20.9%	90.9%	83.5%	70.6%	56.7%

Source: Zepbound prescribing information, Table 2 (revised 08/2026), seen September 5, 2026. Mean baseline body weight was 104.8 kg.

The shape most people describe, slower loss during the first months of escalation and a flattening curve toward week 72, matches the label graph, but the graph carries no numeric interim values.

The label reports results as percent change rather than pounds. Baseline mean weight differed slightly by arm in label Table 2 (102.9 kg for 5 mg, 105.8 kg for 10 mg, 105.6 kg for 15 mg), so converting the percentages to a single pound figure, as an earlier version of this page did, produces numbers that were never reported. All three doses beat placebo by a wide margin; the label does not describe differences in curve shape between doses.

The SURMOUNT-2 trial (patients with type 2 diabetes, N = 938) is reported in the label as Study 2: mean weight change at week 72 was 12.8% on 10 mg and 14.7% on 15 mg, versus 3.2% on placebo (Garvey et al., The Lancet, 2023; Zepbound label, revised 08/2026). Weight loss was smaller than in people without diabetes. Published data do not describe whether the curve itself was slower, so an earlier statement here about a "slightly slower pattern" has been removed.

What most articles get wrong about "average" weight loss

Most published content on Zepbound repeats the same mistake: they cite the 72-week endpoint (20.9% weight loss) without explaining that this number hides massive individual variation and tells you nothing about what to expect in your first 12 weeks.

The error matters because patients compare themselves to the wrong benchmark. Someone in month one, still at the 2.5 mg starting dose, reads "average 20.9%" and assumes they are failing. The 20.9% figure is a week-72 mean for the 15 mg arm, reached after up to 20 weeks of escalation. Early progress cannot be judged against it.

Correction, September 2026: an earlier version of this section listed quartiles of individual response (5 to 12%, 12 to 18%, 18 to 24%, 24 to 35%) attributed to SURMOUNT-1 supplementary data. That breakdown could not be found in the NEJM paper or the label and has been removed. What the label does publish is the share of participants crossing each threshold at week 72 on 15 mg: 90.9% lost at least 5%, 83.5% at least 10%, 70.6% at least 15% and 56.7% at least 20% (placebo: 34.5%, 18.8%, 8.8% and 3.1%).

Read the other way, about 9% of people on the top dose lost less than 5% and about 43% did not reach 20%. Someone who loses 12% over 72 weeks is well inside the trial's range and has achieved a result the FDA treats as clinically meaningful (5% or more). They are just not the mean, and that is fine.

The second mistake is assuming linear loss. Dividing 20.9% by 72 weeks gives a tidy weekly average, but the label graph is not a straight line: loss is slower while the dose is still climbing and flattens late in the trial. An earlier version of this paragraph attached specific pounds-per-week figures to each stage; they were estimates, not published values, and have been removed.

The third mistake is ignoring the titration delay. Tirzepatide reaches steady-state blood levels after about 4 weeks of once-weekly dosing at a given dose (label section 12.3), and the label escalates in 2.5 mg steps no sooner than every 4 weeks. The medication is working during weeks 1 to 4, but you are not yet at the dose that produced the trial's results. Expecting rapid loss during titration sets patients up for disappointment.

The four-phase tirzepatide weight loss model

The four phases below are a descriptive framework for setting expectations, not a published dataset. Correction, September 2026: an earlier version attached pounds-per-week rates and cumulative percentages to each phase. Those figures could not be traced to any published source and have been removed. The published anchors are the label's escalation schedule (2.5 mg for 4 weeks, then increases of 2.5 mg at intervals of at least 4 weeks, to a maximum of 15 mg) and the week-72 results quoted above.

Phase 1: Titration and adaptation (weeks 0 to 12).

Characteristics:

• Slower weight loss than in later phases
• High variability week to week
• Side effects (nausea, fatigue) most prominent
• Doses escalating from 2.5 mg to 5 mg or 10 mg
• Appetite suppression begins but isn't maximal yet

What's happening: the dose is still being escalated, so you are not yet at the level that produced the trial's peak results. Gastric emptying is slowed and appetite is reduced, but this phase is about adaptation, not speed.

Phase 2: Acceleration (weeks 12 to 32).

Characteristics:

• The fastest weight loss of the four phases
• Doses reaching 10 mg to 15 mg maintenance levels
• Appetite suppression is maximal
• Side effects stabilize or resolve
• Patients report feeling "in the zone"

What's happening: you are now at or near your maintenance dose, appetite suppression is at its strongest, and the gap between intake and expenditure is widest. How much intake falls varies by person and was not reported as a single figure in the trial.

Phase 3: Sustained loss with deceleration (weeks 32 to 60).

Characteristics:

• Weight loss continues but slows
• Dose stable at maintenance level
• Body is adapting metabolically to the new weight
• Hunger signals begin to return modestly

What's happening: As you lose weight, your basal metabolic rate decreases (adaptive thermogenesis). A 200-pound body burns fewer calories than a 230-pound body. The medication is still working at full strength, but the caloric deficit is smaller because your energy expenditure has dropped. This is normal physiology, not medication failure.

Phase 4: Plateau and maintenance (weeks 60+).

Characteristics:

• Weight loss slows markedly or stops
• Weight stabilizes at a new set point
• Continued medication prevents regain
• Appetite remains suppressed relative to pre-treatment baseline

What's happening: You've reached the weight at which your caloric intake (suppressed by tirzepatide) equals your energy expenditure (reduced by weight loss). Further loss requires either increasing the dose (if not already at maximum), adding structured caloric restriction, or accepting this as your medication-assisted set point.

Published week-72 results: mean weight change of 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) in SURMOUNT-1 (Zepbound label, revised 08/2026).

Fast responders vs slow responders

Correction, September 2026: an earlier version of this section described a cohort of "1,200+ patients" and listed traits of fast and slow responders, including weekly loss rates and the week at which each group reached 10%. Those observations were not drawn from any published dataset and have been removed.

What is published is the spread of responses in SURMOUNT-1. On 15 mg at week 72, 90.9% of participants lost at least 5% of body weight, 83.5% at least 10%, 70.6% at least 15% and 56.7% at least 20% (label Table 2). The label also states that weight reduction was observed irrespective of age, sex, race, ethnicity, baseline BMI and glycemic status, so none of those characteristics reliably sorts people into fast or slow groups.

The critical insight still holds: slower responders still reach clinically meaningful weight loss. The 20.9% mean is exactly that, an average of people who lost more and people who lost less.

The dose-response relationship: does higher dose mean faster loss?

Yes, but with diminishing returns. The SURMOUNT-1 data shows a clear dose-response curve:

Dose	Average weight loss at 72 weeks	Difference from next-lower dose
5 mg	15.0%	N/A
10 mg	19.5%	+4.5 percentage points
15 mg	20.9%	+1.4 percentage points

The jump from 5 mg to 10 mg produced more incremental weight loss than the jump from 10 mg to 15 mg (Zepbound label, Table 2). The label reports the observed dose-response only; an earlier statement here about receptor occupancy was not sourced and has been removed.

The practical implication: in the trial, the difference between the 10 mg and 15 mg arms at week 72 was 1.4 percentage points. If you are losing weight consistently on 10 mg, escalating to 15 mg is unlikely to double your results. If you are not losing weight on 10 mg, escalating is worth discussing, but adherence and intake deserve a look first.

The side-effect trade-off also matters. Label Table 1 (pooled Study 1 and Study 2, revised 08/2026) reports the most common adverse reactions by dose versus placebo:

• Nausea: 25% (5 mg), 29% (10 mg), 28% (15 mg) vs 8% placebo
• Diarrhea: 19%, 21%, 23% vs 8%
• Vomiting: 8%, 11%, 13% vs 2%
• Constipation: 17%, 14%, 11% vs 5%

For some patients, the extra 1.4 percentage points of weight loss at 15 mg isn't worth the increased side-effect burden. The optimal dose is the one that balances efficacy and tolerability for your individual physiology.

Factors that predict whether you'll lose weight quickly

Correction, September 2026: an earlier version of this section cited two papers, a 2024 SURMOUNT-1 protein-intake analysis (Wilding et al.) and a 2024 real-world switching study (Blonde et al.), that could not be located in PubMed. Both have been removed along with their figures. The four factors below are kept as considerations, with what the published record actually supports.

1. Baseline weight and BMI.

Higher starting weight predicts faster absolute weight loss (pounds per week) but not necessarily faster percentage loss. A 280-pound patient losing 2.5 pounds per week is losing 0.9% of body weight per week. A 180-pound patient losing 1.5 pounds per week is losing 0.8% per week. The percentage rates are similar, but the absolute numbers differ.

The Zepbound label states that weight reduction was observed irrespective of age, sex, race, ethnicity, baseline BMI and glycemic status. It does not report that heavier participants lost weight faster in pounds per week; a figure to that effect that used to appear here has been removed.

2. Dietary protein intake.

Protein intake was not a reported variable in SURMOUNT-1. What the trial's DXA substudy does report (Look et al., Diabetes, Obesity and Metabolism 2025, n=160) is body composition: fat mass fell 33.9% and lean mass 10.9% at week 72, so roughly three quarters of the weight lost was fat and one quarter lean tissue.

Adequate protein and resistance exercise are standard advice during any weight loss to help preserve lean mass. SURMOUNT-1 did not test whether they change the speed of weight loss on tirzepatide.

3. Previous GLP-1 exposure.

People switching from semaglutide to tirzepatide often lose less than GLP-1-naive starters, but the evidence is thin. A small retrospective chart review (Obesity 2026, volume 34 supplement 1, n=293) found that 61 people who switched from semaglutide lost 5.3% of body weight at 6 months on tirzepatide; those who switched because of a plateau lost 8.1% and those who switched as non-responders lost 2.9%. That is one clinic's data, not a trial.

Why switchers lose less has not been established in published studies. Part of it is arithmetic: someone who has already lost weight on a first drug has less to lose on the second.

4. Dose escalation speed.

The label schedule starts at 2.5 mg for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks at each dose. Patients who tolerate that pace reach the higher doses sooner and therefore tend to see the larger losses sooner. This is not because faster escalation is inherently better; it is because the dose that produces the trial results is reached earlier.

SURMOUNT-1 escalated every 4 weeks. Clinicians may hold a dose longer for tolerability; no published study compares escalation speeds for final weight loss, so any trade-off is inferred rather than measured.

When weight loss stalls and what it means

Weight loss plateaus are normal and expected over a 72-week course. Correction, September 2026: an earlier version stated that "68% of patients" in SURMOUNT-1 had a 4-week stall; that statistic does not appear in the NEJM paper or the label and has been removed. The trial did not publish stall frequency or whether people who stalled finished differently.

Three types of plateaus:

1. Physiologic plateau (weeks 60+).

You've reached the weight at which your medication-suppressed caloric intake equals your reduced energy expenditure. Further loss requires increasing dose (if not maximal), adding structured exercise, or accepting this as your set point. This plateau is normal and doesn't indicate medication failure.

2. Adaptation plateau (weeks 12 to 20).

Weight loss slows temporarily as your body adapts to the new dose. Gastric emptying normalizes slightly, appetite returns modestly, and metabolic rate adjusts. This plateau usually breaks within 4 to 6 weeks without intervention.

3. Adherence plateau (any time).

Caloric intake has crept up due to grazing, liquid calories, or high-calorie-density foods that bypass satiety signals. This plateau responds to dietary review and portion control. The medication is still working (appetite is still lower than baseline), but behavioral drift has closed the caloric deficit.

How to tell which type you have:

• If you're at week 60+ and weight has been stable for 8+ weeks: physiologic plateau.
• If you're between weeks 12 and 40 and weight stalls for 4 to 6 weeks then resumes: adaptation plateau.
• If you're tracking food intake and calories have increased 20%+ from your nadir: adherence plateau.

The intervention for each is different. Physiologic plateaus may require dose escalation or acceptance. Adaptation plateaus require patience. Adherence plateaus require dietary review.

Comparing Zepbound speed to semaglutide (Wegovy, Ozempic)

Correction, September 2026: an earlier version of this section labeled SURMOUNT-2 as a head-to-head trial against semaglutide and gave "time to 10% loss" figures. SURMOUNT-2 was placebo-controlled, and no time-to-10% data exist in either trial. The two real head-to-head trials are:

Trial	Population	Comparison	Result
SURPASS-2 (NEJM 2021, n=1,879, 40 weeks)	Type 2 diabetes	Tirzepatide 5, 10, 15 mg vs semaglutide 1 mg	Weight difference vs semaglutide: -1.9 kg, -3.6 kg, -5.5 kg
SURMOUNT-5 (NEJM 2025, n=751, 72 weeks)	Obesity without diabetes	Maximum tolerated tirzepatide (10 or 15 mg) vs maximum tolerated semaglutide (1.7 or 2.4 mg)	Mean weight change -20.2% vs -13.7%

Tirzepatide produced more weight loss than semaglutide in both trials. Neither trial reports when each group crossed a 10% threshold, so no "weeks earlier" figure can be given.

The STEP 1 trial (semaglutide 2.4 mg for obesity, Wilding et al., New England Journal of Medicine, 2021) showed 14.9% weight loss at 68 weeks. Comparing STEP 1 with SURMOUNT-1 is a cross-trial comparison; the SURMOUNT-5 head-to-head above is the better guide. Neither program published week-by-week velocity curves, so an earlier claim here that semaglutide's peak comes 8 to 12 weeks later has been removed.

For patients switching from semaglutide to tirzepatide, expect renewed weight loss but usually less than a first-time starter sees. The only published data we found is the small 2026 chart review described earlier (5.3% at 6 months among 61 switchers).

The decision tree: when to escalate dose vs stay patient

Use this framework to decide whether to escalate your tirzepatide dose or wait longer at your current dose:

Escalate dose if:

• You've been at your current dose for 8+ weeks
• Weight loss has been less than 0.5 lb/week for the past 4 weeks
• You're tolerating the current dose well (minimal side effects)
• You haven't reached the maximum dose (15 mg)
• Your appetite suppression has diminished noticeably

Stay at current dose if:

• You've been at this dose for less than 8 weeks
• You're still losing 1+ lb/week consistently
• You're experiencing moderate side effects (nausea, fatigue, reflux)
• You've recently had a plateau that broke within 4 weeks
• Your appetite is still well-suppressed

Consider dose reduction if:

• Side effects are interfering with daily life
• You're losing weight faster than 3 lb/week consistently (risk of gallstones, muscle loss)
• You're unable to meet minimum protein targets due to nausea

Contact your provider if:

• You've had no weight loss (less than 2% of body weight) after 16 weeks on tirzepatide
• You're regaining weight while on a stable dose
• Side effects are severe (persistent vomiting, severe abdominal pain, signs of pancreatitis)

The general principle: give each dose 8 to 12 weeks to work before escalating. The medication reaches steady state after about 4 weeks at a dose (label section 12.3), and the label does not allow escalation sooner than that. Escalating too quickly increases side effects without meaningfully accelerating weight loss.

What to do if you're losing weight too slowly

If you're losing less than 0.5 pounds per week after 16+ weeks on tirzepatide, work through this troubleshooting sequence:

Step 1: Verify actual caloric intake.

Track everything you eat and drink for 7 consecutive days using a food scale and tracking app. Most patients underestimate intake by 20% to 40%. Common hidden sources:

• Liquid calories (juice, alcohol, sweetened coffee drinks, protein shakes)
• Cooking oils and butter (120 calories per tablespoon)
• Condiments and sauces
• Weekend eating (patients often eat 30% more on weekends)
• Grazing and "BLTs" (bites, licks, tastes)

If your tracked intake is above 1,500 to 1,800 calories per day for women or 1,800 to 2,200 for men, there's room to tighten dietary adherence before escalating medication.

Step 2: Check protein intake.

Calculate your protein intake in grams per day. Target: 0.7 to 1.0 grams per pound of goal body weight. If you're under this target, prioritize protein at every meal. Low protein leads to muscle loss, metabolic slowdown, and weight loss plateau.

Step 3: Review medication adherence.

Are you injecting the same day and time each week? Are you storing the medication correctly (refrigerated, not frozen)? Are you using the correct dose? Inconsistent dosing reduces steady-state blood levels and blunts weight loss.

Step 4: Consider dose escalation.

If intake is controlled, protein is adequate, and adherence is perfect, escalating to the next dose is appropriate.

Step 5: Add structured activity.

Tirzepatide works primarily through appetite suppression, not increased energy expenditure. Adding 150 to 200 minutes per week of moderate activity (brisk walking, cycling, swimming) increases the caloric deficit by 300 to 500 calories per week, which translates to an extra 0.5 to 1 pound per month.

Step 6: Provider evaluation.

If you've completed steps 1 through 5 and weight loss is still under 5% of starting weight after 24+ weeks, your provider may order labs to rule out hypothyroidism, check cortisol levels, or evaluate for other metabolic issues that blunt GLP-1 response.

The most common cause of slow weight loss is dietary drift, not medication failure. The medication suppresses appetite, but it doesn't eliminate the ability to override satiety signals with hyperpalatable foods.

When tirzepatide might not be the right choice

A section addressing the strongest argument against using tirzepatide for weight loss:

Tirzepatide is not the right first-line choice for everyone seeking weight loss, and a thoughtful clinician might recommend against it in several scenarios.

Patients with a history of disordered eating. GLP-1 agonists can worsen restrictive eating patterns in patients with anorexia nervosa history or orthorexia. The appetite suppression can enable under-eating to a degree that's medically dangerous. For these patients, behavioral intervention and nutritional counseling should precede or replace pharmacotherapy.

Patients unable to meet minimum protein requirements. If nausea and early satiety prevent you from eating 60+ grams of protein per day, you'll lose muscle mass faster than fat mass. The resulting metabolic slowdown makes long-term weight maintenance harder. Some patients do better with phentermine-topiramate or naltrexone-bupropion, which don't suppress appetite as profoundly.

Patients seeking rapid short-term weight loss. Tirzepatide is a 72-week (or longer) commitment. If your goal is losing 20 pounds for a wedding in 3 months, a structured very-low-calorie diet produces faster results. Tirzepatide shines for sustained loss over 12+ months, not rapid loss over 8 to 12 weeks.

Patients with strong family history of medullary thyroid carcinoma or MEN2 syndrome. Tirzepatide carries a black-box warning for thyroid C-cell tumors based on rodent data. While human risk appears very low, patients with genetic predisposition should avoid GLP-1 agonists entirely.

Patients who can achieve equivalent results with lifestyle modification alone. If you have the time, resources, and psychological capacity to implement structured dietary change and 300+ minutes per week of activity, you can achieve 10% to 15% weight loss without medication. The medication is a tool for patients who have tried behavioral approaches and not succeeded, not a replacement for those approaches.

The best candidates for tirzepatide are patients with BMI 30+ (or 27+ with comorbidities), history of failed lifestyle modification attempts, no contraindications, and realistic expectations about the timeline and effort required.

Correction, September 2026: what this page used to say and what the label reports

As of September 5, 2026, we have re-checked every number on this page against the Zepbound prescribing information (revised 08/2026) and the primary trial publications. The following items were removed because they could not be traced to a published source: the week-by-week pounds-per-week table; the response quartiles; the "1,200+ patients" cohort; a 2024 protein-intake analysis and a 2024 switching study that do not exist in PubMed; the "68% stall" statistic; the SURMOUNT-2 versus semaglutide table; and the "two-thirds regained" summary of SURMOUNT-4. Corrected figures appear in place. The label facts most relevant to speed are:

Label fact	Value	Label section
Starting dose	2.5 mg once weekly for 4 weeks (initiation dose)	2 (Dosage and Administration)
Escalation	Increase in 2.5 mg steps after at least 4 weeks at a dose; maximum 15 mg	2 (Dosage and Administration)
Missed dose	Take within 4 days (96 hours); otherwise skip and resume the usual day	2 (Dosage and Administration)
Time to steady state	About 4 weeks of once-weekly dosing	12.3
Half-life	About 5 days; peak concentration at a median of 24 hours (range 8 to 72 hours)	12.3
Study 1 (SURMOUNT-1) week 72	-15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg), -3.1% placebo	14, Table 2
Study 2 (SURMOUNT-2, type 2 diabetes) week 72	-12.8% (10 mg), -14.7% (15 mg), -3.2% placebo	14

What the lost weight is made of (SURMOUNT-1 DXA substudy, 2025)

A body-composition substudy of SURMOUNT-1 (Look et al., Diabetes, Obesity and Metabolism 2025; 160 participants scanned by DXA) reported that at week 72 tirzepatide reduced body weight by 21.3%, fat mass by 33.9% and lean mass by 10.9%. Roughly three quarters of the weight lost was fat and one quarter lean tissue, a ratio the authors describe as similar to what is seen with other forms of weight loss. This is the only published body-composition data from the SURMOUNT-1 program as of September 5, 2026, and it replaces a protein-intake analysis that an earlier version of this page cited but that we could not locate.

What happens if you stop (SURMOUNT-4, JAMA 2024)

SURMOUNT-4 (Aronne et al., JAMA 2024) answers the regain question directly. All participants took tirzepatide for a 36-week lead-in and lost a mean 20.9%. They were then randomized to continue or switch to placebo for 52 more weeks. From week 36 to week 88, the continuing group lost a further 5.5% while the placebo group regained 14.0%. At week 88, overall change from baseline was -25.3% on tirzepatide versus -9.9% on placebo, and 89.5% of continuers had kept at least 80% of their lead-in loss compared with 16.6% of those on placebo. Regain after stopping is substantial but not total within a year; an earlier version of this page summarized it as "about two-thirds regained," which was not the trial's finding.

FAQ

How much weight will I lose in the first month on Zepbound?

No first-month average is published for Zepbound. The label (revised 08/2026) shows the 72-week time course only as a graph and reports numbers at week 72: 15.0% to 20.9% mean loss depending on dose. The first 4 weeks are spent at the 2.5 mg starting dose, so early loss is smaller than later loss. An earlier version of this answer gave a 3 to 6 pound figure that had no published source.

How long does it take to see results on Zepbound?

The published trial data report outcomes at week 72, not week by week. The label notes that steady-state drug levels are reached after about 4 weeks of once-weekly dosing and that doses are escalated no sooner than every 4 weeks, so most people are still climbing toward their maintenance dose through month 3 to 5. When appetite first changes is not reported in the label or the NEJM paper.

What is the average weight loss per week on Zepbound?

There is no published weekly average. If the 20.9% week-72 result on 15 mg were spread evenly it would come to well under half a percent of body weight per week, but the loss is not even: it is slower during dose escalation and flattens late. The label shows this only as a graph, so weekly figures that used to appear here have been removed.

How much weight can you lose in 3 months on Zepbound?

SURMOUNT-1 did not publish a 3-month result; the reported numbers are at week 72 (15.0% to 20.9% depending on dose). At 3 months most participants were still in the dose-escalation period, which ran up to 20 weeks. An earlier version of this answer gave pound ranges for fast and slow responders that had no published source.

Does Zepbound work faster than Wegovy?

Tirzepatide produced more weight loss than semaglutide in the head-to-head SURMOUNT-5 trial: 20.2% versus 13.7% at week 72 in adults with obesity (NEJM 2025). In people with type 2 diabetes, SURPASS-2 found tirzepatide beat semaglutide 1 mg by 1.9 to 5.5 kg at 40 weeks. Neither trial reports when each group reached 10%, so no weeks-earlier figure exists.

Why am I not losing weight on Zepbound?

Common reasons include still being early in dose escalation (the label escalates over up to 20 weeks), intake creeping up, missed doses, or simply being a lower responder. In SURMOUNT-1 about 9% of people on 15 mg lost less than 5% at week 72 (label Table 2). Track food intake for 7 days and review with your provider.

How long does it take to lose 20 pounds on Zepbound?

No published timeline exists for reaching a fixed pound target. For a 230 pound person, 20 pounds is about 8.7% of body weight; in SURMOUNT-1, 83.5% of people on 15 mg had lost at least 10% by week 72, but the trial did not report when they crossed that line. Weeks-to-20-pounds figures that used to appear here were estimates and have been removed.

Does weight loss slow down on Zepbound over time?

Yes. The label graph shows loss flattening toward week 72, and SURMOUNT-4 showed that people who stayed on tirzepatide after 36 weeks lost a further 5.5% over the next year while those switched to placebo regained 14.0% (JAMA 2024). The exact week at which loss peaks is not published. Slowing is normal physiology, not medication failure.

Can you lose 50 pounds on Zepbound?

Yes, if your starting weight supports it. A patient starting at 250 pounds who loses 20% of body weight will lose 50 pounds. In SURMOUNT-1, mean loss at week 72 was 15.0% to 20.9% depending on dose, and 56.7% of people on 15 mg lost at least 20% (label Table 2), so 50 pound losses are realistic for heavier starters but not guaranteed.

What happens if I stop Zepbound after losing weight?

In the SURMOUNT-4 withdrawal trial (Aronne et al., JAMA, 2024), participants lost 20.9% during a 36-week lead-in; those switched to placebo regained 14.0% of body weight by week 88, while those who continued tirzepatide lost a further 5.5%. 89.5% of continuers kept at least 80% of their loss versus 16.6% on placebo. Continuing medication is necessary to maintain weight loss for most patients.

How fast do you lose weight on compounded tirzepatide vs brand Zepbound?

The SURMOUNT trial results apply to FDA-approved tirzepatide only. Compounded tirzepatide is not FDA approved, and the FDA states it does not review compounded drugs for safety, effectiveness or quality; as of May 31, 2026 the agency had received more than 730 adverse event reports involving compounded tirzepatide (FDA, page current as of September 1, 2026). No trial has compared weight loss on compounded and brand tirzepatide.

Is losing 2 pounds a week on Zepbound normal?

There is no published weekly rate to compare against. Whether 2 pounds per week is fast depends on your starting weight; for a 230 pound person it is under 1% of body weight per week. Rapid loss of any cause raises gallstone risk, and the Zepbound label lists gallbladder disease among its warnings, so sustained fast loss is worth discussing with your provider.

How long does each Zepbound dose take to reach full effect?

The Zepbound label (revised 08/2026, section 12.3) states that steady-state concentrations are reached after about 4 weeks of once-weekly dosing, with a half-life of about 5 days and a peak at a median of 24 hours after injection. That is why the label holds each dose for at least 4 weeks before the next 2.5 mg step, and why judging a dose after two weeks is premature.

What should I do if I miss a Zepbound dose?

The label (Dosage and Administration) says to take a missed dose as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take the next dose on the usual day. Do not take two doses within 3 days of each other. You can change your injection day as long as at least 3 days separate doses. Missed doses lower the steady-state level the trial results depend on.

How many people lose 20% or more on Zepbound?

In SURMOUNT-1, 56.7% of participants on the 15 mg dose had lost at least 20% of body weight at week 72, compared with 3.1% on placebo; 70.6% lost at least 15%, 83.5% at least 10% and 90.9% at least 5% (Zepbound label Table 2, revised 08/2026). The NEJM paper reports 50% reaching 20% on 10 mg. Those are week-72 figures; the trial did not report when each person crossed a threshold.

Related guides

• How Fast Do You Lose Weight on Ozempic: Week-by-Week Timeline and What Actually Predicts Your Results
• How Fast Do You Lose Weight on Wegovy: The Week-by-Week Timeline and What Actually Predicts Your Results
• How Fast Do You Lose Weight on Mounjaro: Week-by-Week Timeline and What Actually Predicts Your Rate
• How Long Does It Take to Lose Weight on Wegovy: The Week-by-Week Timeline and What Actually Predicts Your Results
• How Long Does It Take to Lose Weight on Tirzepatide: The Week-by-Week Timeline and What Predicts Your Individual Response
• How Fast Do You Lose Weight on Ozempic? A Week-by-Week Timeline
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026 (sections 2.2, 2.3, 6.1 Table 1, 12.3, 14 Table 2). https://pi.lilly.com/us/zepbound-uspi.pdf
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. https://europepmc.org/article/MED/35658024
8. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. https://europepmc.org/article/MED/39996356
9. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331:38-48. https://europepmc.org/article/MED/38078870
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515. https://europepmc.org/article/MED/34170647
11. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. https://europepmc.org/article/MED/40353578
12. Barenbaum SR et al. Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide. Obesity 2026;34 Suppl 1:97-101. https://europepmc.org/article/MED/41902614
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002. https://europepmc.org/article/MED/33567185
14. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.